Julia Emerson, MD, MPH
Research Center: Center for Clinical and Translational Research
-
Julia C. Emerson, MD, MPH, is an epidemiologist in the Division of Pulmonary Medicine at Seattle Children’s Hospital and lecturer in the Department of Pediatrics at the University of Washington School of Medicine. Emerson’s research interests include the natural history of early cystic fibrosis (CF) lung disease, the design of clinical trials to improve CF therapies and the development of better outcome measures for CF clinical protocols. She also collaborates on studies of the genotypic and phenotypic changes in airway pathogens that may be associated with CF lung disease severity and progression.
-
Other Publications
-
Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RLBaseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
20597081 Pediatric pulmonology, 2010 Sept. : 934-44 -
Emerson J, McNamara S, Buccat AM, Worrell K, Burns JLChanges in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
20232473 Pediatric pulmonology, 2010 April : 363-70 -
Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CHReturn of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
20054859 Pediatric pulmonology, 2010 Feb. : 127-34 -
Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JSAssociation of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
19608199 The Journal of pediatrics, 2009 Nov. : 634-9.e1-4 -
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BWEarly anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
19470318 Contemporary clinical trials, 2009 May : 256-68 -
Brannon MK, Davis JM, Mathias JR, Hall CJ, Emerson JC, Crosier PS, Huttenlocher A, Ramakrishnan L, Moskowitz SMPseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos.
19207728 Cellular microbiology, 2009 Feb. 6 -
Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BWImpact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
18822427 The Journal of pediatrics, 2009 Feb. : 183-8 -
Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SIPseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
18974024 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2009 Jan. : 66-70 -
Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RLOral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.
17646219 Chest, 2007 Oct. : 1212-8 -
Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SIUnique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
17763333 The Journal of infectious diseases, 2007 Oct. 1 : 1088-92 -
Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BWDuration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
17534969 Pediatric pulmonology, 2007 July : 610-23 -
Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JLUse of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
16188918 The Journal of antimicrobial chemotherapy, 2005 Nov. : 879-86 -
Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, Davies Z, Foy C, Noone PG, Knowles MRStandardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.
15095320 Pediatric pulmonology, 2004 May : 385-92 -
Moskowitz SM, Foster JM, Emerson J, Burns JLClinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
15131149 Journal of clinical microbiology, 2004 May : 1915-22 -
Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JLUse of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
12958262 Journal of clinical microbiology, 2003 Sept. : 4312-7 -
Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey BSignificant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
12480612 American journal of respiratory and critical care medicine, 2003 March 15 : 841-9 -
Aitken ML, Greene KE, Tonelli MR, Burns JL, Emerson JC, Goss CH, Gibson RLAnalysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
12628880 Chest, 2003 March : 792-9 -
Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken MLDeveloping cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
12406843 American journal of respiratory and critical care medicine, 2002 Dec. 15 : 1550-5 -
Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RLPseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
12112774 Pediatric pulmonology, 2002 Aug. : 91-100
-